Several detachable coil systems are being recalled due to a higher-than-expected failure to detach rate. Customers should not use them going forward.

Survival rates are high for both men and women presenting with BAV disease, according to a new analysis of nearly 28,000 SAVR patients.

Open surgical bypass is the gold standard, but endovascular therapies may provide value for high-risk patients with long femoropopliteal lesions.

New Jersey-based Zydus Pharmaceuticals has recalled nearly 23,000 bottles of its icosapent ethyl capsules due to leakage issues that may have weakened their effectiveness. 

The interventional treatment of tricuspid valve disease has evolved in recent years thanks to new research and critical FDA approvals. Cardiologist Ryan Kaple, MD, reviewed this trend for a new video interview.

Abbott first warned the public about this problem in November. Now, for the second time in less than a month, the FDA is providing additional details. 

The cardiologist at the head of an influential CDC panel sees serious problems with modern vaccine policies. While many experts seem to disagree, one organization has jumped to his defense. 

The annual rankings, based on survey responses and interviews, include a fresh look at some of most important tools in cardiovascular care. 

Nina Goodheart, the president of Medtronic’s structural heart and aortic business, has announced her retirement. 

Cardiology has been shifting from reactionary treatment strategies to a greater emphasis on prevention. This is an especially important trend in heart failure, which is associated with high costs and rising hospitalization rates. 

The intra-annular, self-expanding Navitor valve gained FDA approval in 2023 for the treatment of high-risk heart patients with severe aortic stenosis. This analysis explores its early impact on patient care. 

The CGuard Prime carotid stent system from InspireMD was approved by the FDA in 2025. These data confirm the device's ability to reduce a patient's stroke risk during treatment. 

The self-described “social network for AI agents”—humans can observe but can’t chime in—launched one week ago. But Moltbook already has an awful lot of people fussing and fighting over what it means in the grand scheme of all things AI. 

The Federal Trade Commission was suing the pharmacy benefit manager over allegations it was deliberately inflating the price of insulin. Per the agreement, Express Scripts has agreed to end business practices that involved taking manufacturer rebates on wholesale drug costs without passing them on to patients.